Please assess the completion status of the following clinical trial:

Trial Title: Opioid Use in Single Shot Nerve Block vs Continuous Peripheral Nerve Infusion in Anterior Cruciate Ligament (ACL) Repair

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiology (ASA) physical status 1 or 2~* Male or female subjects ages 14 to 18 years old at time of procedure~* Patients who undergo an ACL repair using the hamstring autograft at The Children's Hospital of Philadelphia~* Parental/guardian permission (informed consent) and if appropriate, child assent~Exclusion Criteria:~* Parents/patients refusal to the placement of a femoral and/or sciatic nerve block~* Contraindications to femoral and/or sciatic nerve block:~  1. Infection~ 2. Neurologic deficits, including motor and/or sensory deficit of the femoral and sciatic nerves.~* Patients' inability to participate in pain scoring because of developmental delay.~* Performance of an all-epiphyseal ACL repair.~* Allergy to any of the medications used in the study.~* Presence of a coagulopathy

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Males Single shot peripheral nerve block (Type: ACTIVE_COMPARATOR): a single injection peripheral nerve block (FS/SS) of the femoral and sciatic nerves, Femoral Block - 0.25% bupivacaine (0.5 ml/kg, max 40 ml). The sciatic block will be performed using 0.125% bupivacaine (0.5 ml/kg, max 20 ml).
- Females Single shot peripheral nerve block (Type: ACTIVE_COMPARATOR): a single injection peripheral nerve block (FS/SS) of the femoral and sciatic nerves, Femoral Block - 0.25% bupivacaine (0.5 ml/kg, max 40 ml). The sciatic block will be performed using 0.125% bupivacaine (0.5 ml/kg, max 20 ml).
- Males Continuous peripheral neural infusion (Type: ACTIVE_COMPARATOR): The placement of a femoral continuous peripheral nerve infusion catheter (CPNI) and 0.25% bupivacaine (0.5 ml/kg, max 20 ml) will be injected under ultrasound guidance.
- Females Continuous peripheral neural infusion (Type: ACTIVE_COMPARATOR): The placement of a femoral continuous peripheral nerve infusion catheter (CPNI) and 0.25% bupivacaine (0.5 ml/kg, max 20 ml) will be injected under ultrasound guidance.

Based on this trial design, predict the completion outcome and termination type (if applicable).